Stifel Financial’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$583K Buy
16,979
+4,564
+37% +$138K ﹤0.01% 2882
2026
Q1
$296K Sell
12,415
-990
-7% -$27.5K ﹤0.01% 3190
2025
Q4
$372K Buy
13,405
+965
+8% +$24.6K ﹤0.01% 3026
2025
Q3
$302K Buy
12,440
+1,599
+15% +$31.8K ﹤0.01% 3106
2025
Q2
$184K Sell
10,841
-513
-5% -$8.93K ﹤0.01% 3270
2025
Q1
$222K Sell
11,354
-2,308
-17% -$60.5K ﹤0.01% 3137
2024
Q4
$339K Buy
13,662
+2,976
+28% +$76K ﹤0.01% 2903
2024
Q3
$262K Buy
+10,686
New +$276K ﹤0.01% 3024
2024
Q2
Sell
-7,626
Closed -$252K 3370
2024
Q1
$252K Buy
+7,626
New +$238K ﹤0.01% 2999
2023
Q3
Sell
-6,777
Closed -$216K 3292
2023
Q2
$216K Sell
6,777
-245
-3% -$7.95K ﹤0.01% 3002
2023
Q1
$215K Buy
7,022
+338
+5% +$13.3K ﹤0.01% 3010
2022
Q4
$261K Sell
6,684
-2,900
-30% -$130K ﹤0.01% 2846
2022
Q3
$457K Buy
+9,584
New +$547K ﹤0.01% 2478
2022
Q2
Sell
-4,241
Closed -$243K 3331
2022
Q1
$243K Buy
4,241
+67
+2% +$4.39K ﹤0.01% 3009
2021
Q4
$332K Buy
4,174
+1,044
+33% +$89.4K ﹤0.01% 2851
2021
Q3
$272K Buy
+3,130
New +$314K ﹤0.01% 2969

Other funds holding BEAM

Stifel Financial's BEAM Position: Q2 2026 in Review

Stifel Financial increased its Beam Therapeutics (BEAM) stake by 37% in Q2 2026, buying an estimated $138K and bringing the position to 16,979 shares worth $583K. The position accounts for ﹤0.01% of the portfolio, ranked #2882.

Stifel Financial first reported a position in BEAM in Q3 2021 and has held it in 16 quarters since. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Stifel Financial held 16,979 shares of Beam Therapeutics worth $583K as of Q2 2026.
  • Stifel Financial bought 4,564 Beam Therapeutics shares in Q2 2026, an estimated $138K.
  • Beam Therapeutics made up ﹤0.01% of Stifel Financial's portfolio in Q2 2026, its #2882 holding.
  • Stifel Financial first reported a position in Beam Therapeutics in Q3 2021 and has held it in 16 quarters since.
  • 278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.